Two SNPs predict lithium response in bipolar I disorder

December 31, 2013
Two SNPs predict lithium response in bipolar I disorder

(HealthDay)—For patients with bipolar I disorder, two single nucleotide polymorphisms (SNPs) in glutamate decarboxylase-like protein 1 (GADL1) predict response to lithium, according to a study published online Dec. 25 in the New England Journal of Medicine.

Noting that many patients with bipolar disorders do not respond to lithium therapy, Chien-Hsiun Chen, Ph.D., from the Institute of Biomedical Sciences in Taipei, Taiwan, and colleagues assessed the response to in subgroups from a sample of 1,761 patients of Han Chinese descent with bipolar I disorder. A genome-wide association study was performed on a subgroup of 294 patients with bipolar I disorder who were receiving lithium. The SNPs with the strongest association with response were assessed in a replication sample of 100 patients and then in a follow-up sample of 24 patients. GADL1 was sequenced in 94 patients with a response to lithium and 94 without.

The researchers found that the strongest associations were seen for rs17026688 and rs17026651 in the genome-wide association study and in the replication sample of 100 patients. The sensitivity for predicting a response to lithium was 93 percent for these two SNPs, and they were able to differentiate between patients with a good and poor response in the follow-up cohort.

"Genetic variations in GADL1 are associated with the response to lithium maintenance treatment for bipolar I disorder in patients of Han Chinese descent," the authors write.

Explore further: The hunt for a successor to lithium for bipolar disorder

More information: Abstract
Full Text

Related Stories

The hunt for a successor to lithium for bipolar disorder

March 27, 2013

Toxicity problems and adverse side effects when taking lithium, the mainstay medication for treating bipolar disorder, are fostering a scientific hunt for insights into exactly how lithium works in the body—with an eye ...

Giving lithium to those who need it

September 21, 2012

Lithium is a 'gold standard' drug for treating bipolar disorder, however not everyone responds in the same way. New research published in BioMed Central's open access journal Biology of Mood & Anxiety Disorders finds that ...

Recommended for you

Teens unlikely to be harmed by moderate digital screen use

January 13, 2017

Parents and pediatricians alike may worry about the effects of teens' screen time, but new findings from over 120,000 adolescents in the UK indicate that the relationship between screen time and well-being is weak at best, ...

Schizophrenia could directly increase risk of diabetes

January 12, 2017

People with early schizophrenia are at an increased risk of developing diabetes, even when the effects of antipsychotic drugs, diet and exercise are taken out of the equation, according to an analysis by researchers from ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.